Clinical trials: Bleeding Diathesis
Congenital Bleeding Disorder, Congenital FVII Deficiency
Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency
This study is conducted in Japan. The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.
- Trial name
- NCT01312636
- Testing
- activated recombinant human factor VII
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Idiopathic Thrombocytopenic Purpura
Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag
This is a single-center, prospective, controlled study with one eltrombopag treatment group and 2 control groups, one on standard steroid treatment, and another one untreated.
- Trial name
- PLATEFUN (NCT00888901)
- Testing
- eltrombopag, corticosteroids (Aprednislon)
- Volunteers
- 30 people
- Sponsor
- Ingrid Pabinger, MD
Thrombocytopathy
Platelet Function in Minimal Extracorporeal Circulation in CABG
Rationale: Cardiac surgery with extracorporeal circulation (ECC) triggers platelets. Minimal extracorporeal circulation system (minimal-ECC) has several advantages compared with conventional ECC amongst less platelet activation.
- Trial name
- ECCTEG (NCT01935245)
- Testing
- Mini extracorporeal circulation, Conventional extracorporeal circulation
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Immune Thrombocytopenia
High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone for the treatment of adults with primary immune…
- Trial name
- NCT01976195
- Testing
- Dexamethasone, Thalidomide
- Where
- China
- Sponsor
- Shandong University
Liposuction, Bruising
EFFECTS OF TRANEXAMIC ACID IN TUMESCENT SOLUTION FOR LIPOSUCTION PROCEDURES
The goal of this trial is to evaluate the effect of adding Tranexamic Acid (TXA) to the tumescent solution used in arm liposuction on postoperative outcomes.
- Conditions
- Liposuction, Bruising, Inflammation, Skin Condition
- Trial name
- ARMTXA (NCT06648265)
- Testing
- Tranexamic Acid (Topical), Tumescent solution with dilute lidocaine and epinephrine
- Where
- Colombia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Total Definer Research Group
Peripheral Venous Catheter Complications, Occlusion
Heparin 100U/L for Prevention of PVC Complications
Flushes with saline solution are used for maintaining patency of peripheral intermittent intravenous catheters in many institution based on the results of previous studies showing that 10 U heparin/mL is not better than saline in…
- Conditions
- Peripheral Venous Catheter Complications, Occlusion, Phlebitis, Ecchymosis
- Trial name
- NCT01131754
- Testing
- heparin 100U/L flushes
- Where
- Italy
- Volunteers
- 214 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Severe Hemophilia A
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with…
- Trial name
- NCT02954575
- Testing
- Wilate
- Where
- 7 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 57 people
- Sponsor
- Octapharma
Postpartum Hemorrhage, Coagulation Disorder
SWIFT - SWIss Factor XIII Trial in PPH
The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH).
- Conditions
- Postpartum Hemorrhage, Coagulation Disorder, Coagulation Factor Deficiency, Hemorrhage
- Trial name
- SWIFT (NCT06481995)
- Testing
- Fibrogammin
- Where
- 9 sites in Switzerland
- Volunteers
- 988 people
- Sponsor
- Christian Haslinger
Hemophilia B
Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B
The primary objective of the study is to assess the safety of IV administration of rIX-FP. Safety will be evaluated by adverse events and laboratory changes over time.
- Trial name
- NCT01233440
- Testing
- Recombinant Coagulation Factor IX Albumin Fusion Protein, Plasma derived FIX [pdFIX]
- Where
- 20 sites in Austria, France and 4 more
- Volunteers
- 25 people
- Sponsor
- CSL Behring
Immune Thrombocytopenia
Treatment of ITP With Rituximab and / or Accutane
a prospective, multicenter, randomized, open-label, Phase II, two arms interventional trial performed in 5 departments of hematology in China
- Trial name
- NCT02757196
- Testing
- Rituximab plus methylprednisolone, methylprednisolone
- Volunteers
- 112 people
- Sponsor
- Peking University People's Hospital
Primary Immune Thrombocytopenia
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia…
- Trial name
- myOpportunITy2 (NCT04224688)
- Testing
- Rozanolixizumab
- Where
- 29 sites in United States, Bulgaria and 9 more
- Volunteers
- 30 people
- Sponsor
- UCB Biopharma SRL
Haemophilia A, Factor VIII
Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
Hemophilia A is an inherited bleeding disorder caused by the absence or deficiency of coagulation factor VIII. The perioperative management of individuals with hemophilia A involves replacement therapies, typically through bolus…
- Trial name
- CHALE II (NCT07723560)
- Testing
- Clinical Data
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Hospices Civils de Lyon
Immune Thrombocytopenic Purpura, Thyroid Disorders
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment
- Trial name
- NCT07059910
- Testing
- Search for thyroid disorders, Laboratory test, Steroid and eltrombopage
- Volunteers
- 100 people
- Sponsor
- Assiut University
Immune Thrombocytopenia (ITP)
Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia
Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia
- Trial name
- NCT07046013
- Testing
- Lactate dehydrogenase
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sohag University
Immune Thrombocytopenic Purpura
Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura
Patients with chronic immune thrombocytopenic purpura (ITP) live with an anxiety-inducing risk of haemorrhage that is unpredictable over several months or years.
- Trial name
- ITP-CPET (NCT07310342)
- Testing
- IPT-CPET
- Where
- 5 sites in France
- Volunteers
- 53 people
- Sponsor
- University Hospital, Bordeaux
Autoimmune Thrombocytopenia
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
This is a single-arm, open-label，phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.
- Trial name
- NCT06826430
- Testing
- Inaticabtagene autoleucel Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Juventas Cell Therapy Ltd.
Hemophilia B
Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B
In this study a modified virus called adeno-associated virus (AAV) will be used to transfer a normal gene for human clotting factor IX into patients with severe hemophilia B (AAV human Factor IX vector).
- Trial name
- NCT00076557
- Testing
- Adeno-Associated Viral with Human Factor IX
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Avigen
Hemophilia A
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
The joint status (knees, ankles) of patients suffering from severe Hemophilia A (too little blood clotting factor VIII in blood) is evaluated in a single magnetic resonance imaging session. No study medication is given.
- Trial name
- NCT00927667
- Testing
- No Drug
- Where
- 15 sites in Germany, Greece and 4 more
- Volunteers
- 156 people
- Sponsor
- Bayer
Stroke, Ischemic, Transient Ischemic Attack
Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke
Annually 100,000 strokes occur, placing stroke as the largest cause of disability in the UK. 90% of strokes are preventable, leading to national focus on programmes including "The National Stroke Programme" to act on preventing…
- Conditions
- Stroke, Ischemic, Transient Ischemic Attack, Coagulation Disorder
- Trial name
- PREDICT-EV (NCT05645081)
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Cwm Taf University Health Board (NHS)
Sepsis and Coagulopathy
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- Scarlet2 (NCT03517501)
- Testing
- ART-123
- Sponsor
- Asahi Kasei Pharma America Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.